Editas Medicine, Inc. (EDIT) stock
EDITNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 3/3047% above fair value
$2.38−0.13 (-4.99%)
Close on Nov 11, 2026Market cap $365.52MP/E –Yield –
Editas Medicine profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Editas Medicine's profit margin for the twelve months ending Sep 30, 2026 was -145.0%. For fiscal 2025 it was -395.0%, against -733.7% the year before. The highest annual figure on record is -127.8% in fiscal 2020.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -395.0% | +338.7 |
| FY2024 | Dec 31, 2024 | -733.7% | −537.6 |
| FY2023 | Dec 31, 2023 | -196.1% | +922.1 |
| FY2022 | Dec 31, 2022 | -1118.3% | −364.7 |
| FY2021 | Dec 31, 2021 | -753.6% | −625.8 |
| FY2020 | Dec 31, 2020 | -127.8% | +523.6 |
| FY2019 | Dec 31, 2019 | -651.4% | −307.2 |
| FY2018 | Dec 31, 2018 | -344.3% | +532.2 |
| FY2017 | Dec 31, 2017 | -876.5% | +729.0 |
| FY2016 | Dec 31, 2016 | -1605.5% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -225.7% | +107.3 |
| Q2 FY2026 | Jun 30, 2026 | -153.3% | +1334.5 |
| Q1 FY2026 | Mar 31, 2026 | -882.4% | +751.0 |
| Q4 FY2025 | Dec 31, 2025 | -22.7% | +125.6 |
| Q3 FY2025 | Sep 30, 2025 | -333.0% | +101537.5 |
| Q2 FY2025 | Jun 30, 2025 | -1487.8% | +11690.9 |
| Q1 FY2025 | Mar 31, 2025 | -1633.5% | +3824.7 |
| Q4 FY2024 | Dec 31, 2024 | -148.3% | −116.9 |
| Q3 FY2024 | Sep 30, 2024 | -101870.5% | −101026.8 |
| Q2 FY2024 | Jun 30, 2024 | -13178.8% | −11783.2 |
| Q1 FY2024 | Mar 31, 2024 | -5458.1% | −4960.4 |
| Q4 FY2023 | Dec 31, 2023 | -31.4% | +897.9 |
| Q3 FY2023 | Sep 30, 2023 | -843.7% | +131837.3 |
| Q2 FY2023 | Jun 30, 2023 | -1395.6% | −555.4 |
| Q1 FY2023 | Mar 31, 2023 | -497.8% | +248.3 |
| Q4 FY2022 | Dec 31, 2022 | -929.3% | −597.0 |
| Q3 FY2022 | Sep 30, 2022 | -132681.0% | −132050.3 |
| Q2 FY2022 | Jun 30, 2022 | -840.2% | +13739.2 |
| Q1 FY2022 | Mar 31, 2022 | -746.0% | +126.8 |
| Q4 FY2021 | Dec 31, 2021 | -332.3% | +215.0 |
| Q3 FY2021 | Sep 30, 2021 | -630.7% | −643.1 |
| Q2 FY2021 | Jun 30, 2021 | -14579.4% | −14360.1 |
| Q1 FY2021 | Mar 31, 2021 | -872.9% | −213.7 |
| Q4 FY2020 | Dec 31, 2020 | -547.3% | −239.9 |
| Q3 FY2020 | Sep 30, 2020 | 12.4% | +868.5 |
| Q2 FY2020 | Jun 30, 2020 | -219.3% | +1230.7 |
| Q1 FY2020 | Mar 31, 2020 | -659.2% | +754.5 |
| Q4 FY2019 | Dec 31, 2019 | -307.5% | +102.0 |
| Q3 FY2019 | Sep 30, 2019 | -856.1% | −751.1 |
| Q2 FY2019 | Jun 30, 2019 | -1450.0% | −924.8 |
| Q1 FY2019 | Mar 31, 2019 | -1413.7% | −625.8 |
| Q4 FY2018 | Dec 31, 2018 | -409.4% | +577.4 |
| Q3 FY2018 | Sep 30, 2018 | -105.0% | +318.5 |
| Q2 FY2018 | Jun 30, 2018 | -525.3% | +328.4 |
| Q1 FY2018 | Mar 31, 2018 | -787.9% | +3771.8 |
| Q4 FY2017 | Dec 31, 2017 | -986.9% | – |
| Q3 FY2017 | Sep 30, 2017 | -423.4% | – |
| Q2 FY2017 | Jun 30, 2017 | -853.7% | – |
| Q1 FY2017 | Mar 31, 2017 | -4559.7% | – |
See a number that looks wrong?